1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Human |
Cat.No | ABC-TC3951 |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Mononuclear Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Peripheral Blood |
Disease | Multiple Myeloma |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Relapsed/Refractory) are derived from the peripheral blood of patients diagnosed with relapsed or refractory multiple myeloma, a highly aggressive plasma cell malignancy. Round or quasi-round suspended cells with weak adhesion; intracytoplasmic vacuolation and enlarged nucleoli. Cell morphology is characterized by suspended growth of round or quasi-round cells with weak wall adhesion. Typical MM cells show intracytoplasmic vacuolation and enlarged nucleoli. High abnormal monoclonal immunoglobulin expression; Cereblon mutations; overexpression of peptidyl prolyl isomerase A (PPIA) linked to drug resistance.This cell line highly expresses abnormal monoclonal immunoglobulins and has significant drug resistance characteristics, such as resistance to immunomodulators such as lenalidomide and pomalidomide and proteasome inhibitors. The resistance mechanism is related to Cereblon protein mutation and overexpression of peptidyl propionyl isomerase A (PPIA)
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Relapsed/Refractory) are an important model for studying the interaction between tumor resistance mechanisms and the myeloma microenvironment. This cell can be used as an in vitro validation platform for: 1) exploring key targets of resistance (such as Cereblon mutations and PPIA overexpression); 2) evaluating the efficacy of new immunotherapies, including BCMA/CD19 bispecific CAR-T cells and GPRC5D targeting antibodies; 3) developing innovative treatment options such as bispecific antibodies. Its unique resistance characteristics and primary cell characteristics provide an irreplaceable experimental system for precision treatment research of multiple myeloma.